Strategies to discover novel antimicrobials to cope with emerging medical needs

Antimicrobials: New and Old Molecules in the Fight Against Multi-Resistant Bacteria

Volumn 9783642399688, Issue , 2014, Pages 327-360

  Genilloud, Olga ^a   Vicente, Francisca ^a  

^a Health Sciences Technology Park   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930246440     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-39968-8_17     Document Type: Chapter

References (112)

1. Barb AW, Zhou P (2008) Mechanism and Inhibition of LpxC: An essential zinc-dependent deacetylase of bacterial lipid A synthesis. Curr Pharm Biotechnol 9:9-15
2. Barb A, Jiang L, Raetz C, Zhou P (2007) Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci U S A 104:18433-18438
3. Benowitz AB, Hoover JL, David J, Payne DJ (2010) Antibacterial drug discovery in the age of resistance. Microbe 5:390-396
4. Bernander R, Akerlund T, Nordström K (1995) Inhibition and restart of initiation chromosome replication: effects on exponentially growing Escherichia coli cells. J Bacteriol 177:1670-1682
5. Bui NK, Eberhardt A, Vollmer D, Kern T, Bougault C, Tomasz A, Simorre JP, Vollmer W (2012) Isolation and analysis of cell wall components from Streptococcus pneumoniae. Anal Biochem 421:657-666
6. Butler MS, Cooper MA (2011) Antibiotics in the clinical pipeline in 2011. J Antibiot 64:413-425
7. Carl PL (1970) Escherichia coli mutants with temperature-sensitive synthesis of DNA. Mol Gen Genet 109:107-122
8. Carlson HA, McCammon JA (2000) Accommodating protein flexibility in computational drug design. Mol Pharmacol 57:213-218
9. Chan DC, Laughton CA, Queener SF, Stevens MF (2001) Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase. J Med Chem 44:2555-2564
10. Chan PF, Holmes DJ, Payne DJ (2004) Finding the gems using genomic discovery: Antibacterial drug discovery strategies-the successes and the challenges. Drug Discov Today 1:519-527
11. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ, Yuan Z (2000) Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39:1256-1262
12. Chen D, Hackbarth C, Ni ZJ, Wu C, Wang W, Jain R, He Y, Bracken K, Weidmann B, Patel DV, Trias J, White RJ, Yuan Z (2004) Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob Agents Chemother 48:250-261
13. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, Salzberg AC, Huang E (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25:71-75
14. D'Elia M, Henderson J, Beveridge T, Heinrichs D, Brown E (2009) The N-acetylmannosamine transferase catalyzes the first committed step in teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 191:4030-4034
15. Darst SA (2001) Bacterial RNA polymerase. Curr Opin Struct Biol 11:155-162
16. De la Cruz M, Robles A, González I, Salazar O, Feliz J, Cercenado MI, Martín J, González del Val A, Tormo JR, Hernández P, Onishi R, Parish C, Zink DL, Cully D, Genilloud O, Díez MT, Peláez F, Vicente MF (2006) Ramoplanin-related components produced by Actinomycetes. The 2nd FEMS Congreso of European Microbiologists, Madrid, Spain
17. De la Cruz M, El Aouad N, Jiménez E, Palomo S, González I, Tormo R, Martín J, Genilloud O, Reyes F, Vicente F (2011) Estudio preliminar de la caracterización biológica y química de análogos de ramoplanina aislados de Actinomicetos. XXIII Congreso de la Sociedad Española de Microbiología. SEM2011. Salamanca, Spain DeCenzo
18. M, Kuranda M, Cohen S, Babiak J, Jiang ZD, Su D, Hickey M, Sancheti P, Bradford PA, Youngman P, Projan S, Rothstein DM (2002) Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria. J Antibiot 55:288-295
19. DeWeese-Scott C, Moult J (2004) Molecular modeling of protein function regions. Proteins 55:942-961
20. Donadio S, Monciardini P, Alduina R, Mazza P, Chiocchini C, Cavaletti L, Sosio M, Puglia AM (2002) Microbial technologies for the discovery of novel bioactive metabolites. J Biotechnol 99:187-198
21. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D (2010) Antibiotic discovery in the twenty-first century: Current trends and future perspectives. J Antibiot 63:423-430
22. Donald RG, Skwish S, Forsyth RA, Anderson JW, Zhong T, Burns C, Lee S, Meng X, LoCastro L, Jarantow LW, Martin J, Lee SH, Taylor I, Robbins D, Malone C, Wang L, Zamudio CS, Youngman PJ, Phillips JW (2009) A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. Chem Biol 16:826-836
23. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, Zugay JA, Emini EA, Schleif WA, Quintero JC et al (1994) L-735, 524: The design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 37:3443-3451
24. Fabbretti A, Gualerzi CO, Brandi L (2011) How to cope with the quest for new antibiotics. FEBS Lett 585(11):1673-1681
25. Fischbach MA, Walsh CT (2009) Antibiotics for emerging pathogens. Science 325:1089-1093
26. Freiberg C, Brötz-Oesterhelt H (2005) Functional genomics in antibacterial drug discovery. Drug Discov Today 10:927-935
27. Forsyth RA, Haselbeck RJ, Ohlsen KL, Yamamoto RT, Xu H, Trawick JD, Wall D, Wang L, Brown-Driver V, Froelich JM, C KG, King P, McCarthy M, Malone C, Misiner B, Robbins D, Tan Z, Zhu Zy ZY, Carr G, Mosca DA, Zamudio C, Foulkes JG, Zyskind JW (2002). A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol 43:1387-1400
28. Gadebush HH, Stapley EO, Zimmerman SB (1992) The discovery of cell wall active antibacterial antibiotics. Crit Rev Biotechnol 12:225-243
29. Genilloud O (2012) Current challenges in the discovery of novel antibacterials from microbial natural products. Recent Pat Antiinfect Drug Discov 7:189-204
30. Genilloud O, González I, Salazar O, Martín J, Tormo JR, Vicente F (2011) Current approaches to exploit actinomycetes as a source of novel natural products. J Ind Microbiol Biotechnol 38:375-389
31. Goetz MA, Zhang C, Zink DL, Arocho M, Vicente F, Bills GF, Polishook J, Dorso K, Onishi R, Gill C, Hickey E, Lee S, Ball R, Skwish S, Donald RG, Phillips JW, Singh SB (2010) Coelomycin, a highly substituted 2, 6-dioxo-pyrazine fungal metabolite antibacterial agent discovered by Staphylococcus aureus fitness test profiling. J Antibiot 63:512-518
32. Grompe M, Versalovic J, Koeuth T, Lupski JR (1991) Mutations in the Escherichia coli dnaG gene suggest coupling between DNA replication and chromosome partitioning. J Bacteriol 173:1268-1278
33. Grundling A, Schneewind O (2007) Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus. Proc Natl Acad Sci U S A 104:8478-8483
34. Guilloteau JP, Mathieu M, Giglione C, Blanc V, Dupuy A, Chevrier M, Gil P, Famechon A, Meinnel T, Mikol V (2002) The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: A platform for the structure-based design of antibacterial agents. J Mol Biol 320:951-962
35. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ (2010) Challenges of antibacterial discovery revisited. Ann N Y Acad Sci 1213:5-19
36. Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49:377-389
37. Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG (2008) An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321:1673-1675
38. Hirota Y, Mordoh J, Jacob F (1970) On the process of cellular division in Escherichia coli. 3. Thermosensitive mutants of Escherichia coli altered in the process of DNA initiation. J Mol Biol 53:369-387
39. Hooper DC, Wolfson JS, McHugh GL, Winters MB, Swartz MN (1982) Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob Agents Chemother 22:662-671
40. Hurdle JG, O'Neill AJ, Chopra I (2005) Prospects for Aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother 49:4821-4833
41. Jain AN (2007) Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search (2013). J Comput Aided Mol Des 21:281-306
42. Jain R, Chen D, White RJ, Patel DV, Yuan Z (2005) Bacterial peptide deformylase inhibitors: A new class of antibacterial agents. Curr Med Chem 12:1607-1621
43. Jayasuriya H, Herath KB, Zhang C, Zink DL, Basilio A, Genilloud O, Díez MT, Vicente F, González I, Salazar O, Peláez F, Cummings R, Ha S, Wang J, Singh SB (2007) Isolation and structure of platencin: A FabH and FabF dual inhibitor with potent broad-spectrum antibiotic activity. Angew Chem Int Ed Engl 46:4684-4688
44. Kapoor S, Panda D (2009) Targeting FtsZ for antibacterial therapy: A promising avenue. Expert Opin Ther Targets 13:1037-1051
45. Keyser P, Elofsson M, Rosell S, Wolf-Watz H (2008) Virulence blockers as alternatives to antibiotics: Type III secretion inhibitors against Gram-negative bacteria. J Intern Med 264:17-29
46. Kirst HA (2012) Recent derivatives from smaller classes of fermentation-derived antibacterials. Expert Opin Ther Patents 22:15-35
47. Kirst HA (2013) Developing new antibacterials through natural product research. Expert Opin Drug Discov 8:479-493
48. Konrad EB (1977) Method for the isolation of duplications between chromosomal enhanced recombination Escherichia coli mutants with. J Bacteriol 130:167-172
49. Langsdorf EF, Malikzay A, Lamarr WA, Daubaras D, Kravec C, Zhang R, Hart R, Monsma F, Black T, Ozbal CC, Miesel L, Lunn CA (2010) Screening for antibacterial inhibitors of the UDP-3-O-(R-3-Hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a highthroughput mass spectrometry assay. J Biomol Screen 15:52-61
50. Lederberg J (1956) Bacterial protoplasts Induced by penicillin. Proc Natl Acad Sci U S A. 42:574-577
51. Ligozzi M, Pittaluga F, Fontana R (1993) Identification of a genetic element (psr) which negatively controls expression of Enterococcus hirae penicillin-binding protein 5. J Bacteriol 175:2046-2051
52. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès JM (2007) Antibiotic efflux pumps in Gram-negative bacteria: The inhibitor response strategy. J Antimicrob Chemother 59:1223-1229
53. Mani N, Sancheti P, Jiang ZD, McNaney C, DeCenzo M, Knight B, Stankis M, Kuranda M, Rothstein DM (1998) Screening systems for detecting inhibitors of cell wall transglycosylation in Enterococcus. Cell wall transglycosylation inhibitors in Enterococcus. J Antibiot 51:471-479
54. Mansour TS, Caufield CE, Rasmussen B, Chopra R, Krishnamurthy K, Morris M, Svenson K, Bard J, Smeltzer C, Naughton S, Antane S, Yang Y, Severin A, Quagliato D, Petersen PJ, Singh G (2007) Naphthyl tetronic acids as multi-target inhibitors of bacterial peptidoglycan biosynthesis. Chem Med Chem 2:1414-1417
55. Mascher T, Zimmer SL, Smith TA, Helmann JD (2004) Antibiotic-inducible promoter regulated by the cell envelope stress-sensing two-component system LiaRS of Bacillus subtilis. Antimicrob Agents Chemother 48:2888-2896
56. Mazel D, Pochet S, Marliere P (1994) Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J 13:914-923
57. McClerren A, Endsley S, Bowman J, Andersen N, Guan Z, Rudolph J, Raetz C (2005) A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin. Biochemistry 44:16574-16583
58. Meinnel T, Blanquet S (1993) Evidence that peptide deformylase and methionyl-tRNA(fMet) formyltransferase are encoded within the same operon in Escherichia coli. J Bacteriol 175:7737-7740
59. Monneret C (2013) Four new drugs on the market: Abiraterone, belatacept, vandetanib and fidaxomicin. Ann Pharm 71:95-103
60. Mori H, Ito K (2001) The Sec protein-translocation pathway. Trends Microbiol 9:494-500
61. Mullane KM, Gorbach S (2011) Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 9:767-777
62. Murakami R, Muramatsu Y, Minami E et al (2009) A novel assay of bacterial peptidoglycan synthesis for natural product screening. J Antibiot 62:153-158
63. Novak R (2012) Retapamulin: A first-in-class pleuromutilin antibiotic. In: Genilloud O, Vicente F (eds) Drug discovery from natural products. RSC Publishing, London
64. Oldfield E (2010) Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Acc Chem Res 43:1216-1226
65. Oluyinka MG, McKenziea AR, Shapiroa AB, Otterbeinb L, Nic H, Pattena A, Stokesa S, Alberta R, Kawatkara S, Breedd J (2012) Inhibitors of acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphateacetyltransferase (GlmU). Part 1: Hit to lead evaluation of a novel arylsulfonamide series. Bioorg Med Chem Lett 22:1510-1519
66. Ondeyka JG, Zink DL, Young K, Painter R, Kodali S, Galgoci A, Collado J, Tormo JR, Basilio A, Vicente F, Wang J, Singh SB (2006) Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy. J Nat Prod 69:377-380
67. Ondeyka JG, Zink D, Basilio A, Vicente F, Bills G, Diez MT, Motyl M, Dezeny G, Byrne K, Singh SB (2007) Coniothyrione, a chlorocyclopentandienyl benzopyrone as a bacterial protein synthesis inhibitor discovered by antisense technology. J Nat Prod 70:668-670
68. Onishi HR, Pelak BA, Gerckens LS, Silver LL, Kahan FM, Chen MH, Patchett AA, Galloway SM, Hyland SA, Anderson MS, Raetz CRH (1996) Antibacterial agents that inhibit lipid A biosynthesis. Science 274:980-982
69. Overbye KM, Barrett JF (2005) Antibiotics: where did we go wrong? Drug Discov Today. 10:45-52
70. Parish CA, de la Cruz M, Smith SK, Zink D, Baxter J, Tucker-Samaras S, Collado J, Platas G, Bills G, Díez MT, Vicente F, Peláez F, Wilson K (2009) Antisense-guided isolation and structure elucidation of pannomycin, a substituted cis-decalin from Geomyces pannorum. J Nat Prod 72:59-62
71. Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf WE Jr, Fosberry AP Jr, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF (2002) Discovery of a novel and potent class of FabIdirected antibacterial agents. Antimicrob Agents Chemother 46:3118-3124
72. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29-40
73. Pereira MP, Blanchard JE, Murphy C, Roderick SL, Brown ED (2009) High-throughput screening identifies novel inhibitors of the acetyltransferase activity of Escherichia coli GlmU. Antimicrob Agents Chemother 53:2306-2311
74. Peterson EJR, Janzen WP, Kireev D, Singleton SF (2012) High-throughput screening for RecA inhibitors using a Transcreener Adenosine 5-O-diphosphate assay. Assay Drug Dev Technol 10:260-268
75. Phillips JW, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, Lee S, Skwish S, de la Cruz M, Martín J, Vicente F, Genilloud O, Lu J, Painter RE, Young K, Overbye K, Donald RG, Singh SB (2011) Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemicalgenetic profiling in Staphylococcus aureus. Chem Biol 18:955-965
76. Schaus N, O'Day K, Peters W, Wright A (1981) Isolation and characterization of amber mutations in gene dnaA of Escherichia coli K-12. J Bacteriol 145:904-913
77. Schimmel P, Tao J, Hill J (1998) Aminoacyl tRNA synthetases as targets for new anti-infective. FASEB J 12:1599-1609
78. Schmid MB (2006) Crystallizing new approaches for antimicrobial drug discovery. Biochem Pharmacol 71:1048-1056
79. Silver LL (2006) Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? Biochem Pharmacol 71:996-1005
80. Silver LL (2011) Challenges of antibacterial discovery. Clin Microbiol Rev 24:71-109
81. Silver LL (2012) Rational approaches to antibacterial discovery: pre-genomic directed and phenotypic screening. In: Dougherty TJ, Pucci MJ (eds) Antibiotic discovery and development. Springer Science, New York
82. Silver L, Bostian K (1990) Screening of natural products for antimicrobial agents. Eur J Clin Microbiol Infect Dis 9:455-461
83. Singh SB, Zink DL, Huber J, Genilloud O, Salazar O, Diez MT, Basilio A, Vicente F, Byrne KM (2006) Discovery of lucensimycins A and B from Streptomyces lucensis MA7349 using an antisense strategy. Organic Lett 8:5449-5452
84. Singh SB, Phillips JW, Wang J (2007) Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing. Curr Opin Drug Discov Devel 10:160-166
85. Singh SB, Young K, Miesel L (2011) Screening strategies for discovery of antibacterial natural products. Expert Rev Anti Infect Ther 9:589-613
86. Srivastava A, Talaue M, Liu S, Degen D, Ebright RY, Sineva E, Chakraborty A, Druzhinin SY, Chatterjee S, Mukhopadhyay J, Ebright YW, Zozula A, Shen J, Sengupta S, Niedfeldt RR, Xin C, Kaneko T, Irschik H, Jansen R, Donadio S, Connell N, Ebright RH (2011) New target for inhibition of bacterial RNA polymerase: 'switch region'. Curr Opin Microbiol 14:532-543
87. Sugie Y, Inagaki S, Kato Y, Nishida H, Pang CH, Saito T, Sakemi S, Dib-Hajj F, Mueller JP, Sutcliffe J, Kojima Y (2002) CJ-21, 058, a new SecA inhibitor isolated from a fungus. J Antibiot 55:25-29
88. Sun D, Cohen S, Mani N, Murphy C, Rothstein DM (2002) A pathway-specific cell based screening system to detect bacterial cell wall inhibitors. J. Antibiotics 55:279-287
89. Tholander F, Sjöberg BM (2012) Discovery of antimicrobial ribonucleotide reductase inhibitors by screening in microwell format. Proc Natl Acad Sci U S A 109:9798-9803
90. Tomasić T, Masic LP (2009) Rhodanine as a privileged scaffold in drug discovery. Curr Med Chem 16:1596-1629
91. Trusca D, Bramhill D (2002) Fluorescent assay for polymerization of purified bacterial FtsZ celldivision protein. Anal Biochem 307:322-329
92. Urban A, Eckermann S, Fast B, Metzger S, Gehling M, Ziegelbauer K, Rübsamen-Waigmann H, Freiberg C (2007) Novel whole-cell antibiotic biosensors for compound discovery. Appl Environ Microbiol 73:6436-6443
93. Venugopal AA, Johnson S (2012) Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 54:568-574
94. Villoutreix BO, Renault N, Lagorce D, Sperandio O, Montes M, Miteva MA (2007) Free resources to assist structure-based virtual ligand screening experiments. Curr Protein Pept Sci 8:381-411
95. Wang J (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 3:430-440
96. Wang J, Galgoci A, Kodali S, Herath KB, Jayasuriya H, Dorso K, Vicente F, González A, Cully D, Bramhill D, Singh S (2003) Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J Biol Chem 278:44424-44428
97. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, Zhang CW, Hernandez L, Allocco J, Basilio A, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C, Silver LL, Hermes JD, Bartizal K, Barrett J, Schmatz D, Becker JW, Cully D, Singh SB (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441:358-361
98. Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti SL, Herath K, Cummings R, Salazar O, González I, Basilio A, Vicente F, Genilloud O, Peláez F, Jayasuriya H, Young K, Cully DF, Singh SB (2007) Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci USA 104:7612-7616
99. Weidenmaier C, Peschel A, Xiong Y, Kristian S, Dietz K, Yeaman M, Bayer A (2005) Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J Infect Dis 191:1771-1777
100. Weisblum B, Haenssler E (1974) Fluorometric properties of the bibenzimidazole derivative Hoechst 33258, a fluorescent probe specific for AT concentration in chromosomal DNA. Chromosoma 46:255-260
101. Wigle TJ, Sexton JZ, Gromova AV, Hadimani MB, MA, GR, Yeh L-A, Singleton SF (2009) Inhibitors of RecA activity discovered by high-throughput screening: Cell-permeable small molecules attenuate the SOS response in Escherichia coli. J Biomol Screen 14:1092-1101
102. Wilson KE, Tsou NN, Guan Z, Ruby CL, Pelaez F, Gorrochategui J, Vicente F, Onishi HR (2000) Isolation and structure elucidation of coleophomones A and B, novel inhibitors of bacterial cell wall transglycosylase. Tetrahedron Lett 41:8705-8709
103. Wimberly BT (2009) The use of ribosomal crystal structures in antibiotic drug design Curr Opin Investig Drugs 10:750-65
104. Wong KK, Pompliano DL (1998) Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathway. Adv Exp Med Biol 456:197-217
105. Wright GD, Sutherland AD (2007) New strategies for combating multidrug-resistant bacteria. Trends Mol Med 13:260-267
106. Yang LP, Keam SJ (2008) Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 68:855-873
107. Yang JS, Chen WW, Skolnick J, Shakhnovich EI (2007) All-atom ab initio folding of a diverse set of proteins. Structure 15:53-63
108. Young K, Jayasuriya H, Ondeyka JG, Herath K, Zhang CW, Kodali S, Galgoci A, Painter R, Brown-Driver V, Yamamoto R, Silver LL, Zheng YC, Ventura JI, Sigmund J, Ha S, Basilio A, Vicente F, Tormo JR, Pelaez F, Youngman P, Cully D, Barrett JF, Schmatz D, Singh SB, Wang J (2006) Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother 50:519-526
109. Yuan Z, Trias J, White RJ (2001) Deformylase as a novel antibacterial target. Drug Discov Today 6:954-961
110. Zhang C, Occi J, Masurekar P, Barrett JF, Zink DL, Smith S, Onishi R, Ha S, Salazar O, Genilloud O, Basilio A, Vicente F, Gill C, Hickey EJ, Dorso K, Motyl M, Singh SB (2008) Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347. J Am Chem Soc 130:12102-12110
111. Zhao Y, Sanner MF (2007) FLIPDock: docking flexible ligands into flexible receptors. Proteins 68:726-737
112. Zhu W, Zhang Y, Sinko W, Hensler ME, Olson J, Molohon KJ, Lindert S, Cao R, Li K, Wang K, Wang Y, Liu YL, Sankovsky A, de Oliveira CA, F, Mitchell DA, Nizete V, McCammon JA, Oldfielda E (2013) Antibacterial drug leads targeting isoprenoid biosynthesis. Proc Natl Acad Sci U S A 110:123-128